Radiotherapy combined with deep regional hyperthermia in elderly and frail patients with muscle-invasive bladder cancer: quality analysis of hyperthermia and impact on clinical results

References

• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866. doi: 10.1056/NEJMoa022148.
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675. doi: 10.1200/JCO.2001.19.3.666.
   PubMed Web of Science ®Google Scholar
• Zaid HB, Patel SG, Stimson CJ, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the national cancer database. Urology. 2014;83(1):75–80. doi: 10.1016/j.urology.2013.07.072.
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Ballas LK, Niemierko A, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023;24(6):669–681. doi: 10.1016/S1470-2045(23)00170-5.
   PubMed Web of Science ®Google Scholar
• Vashistha V, Wang H, Mazzone A, et al. Radical cystectomy compared to combined modality treatment for Muscle-Invasive bladder cancer: a systematic review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2017;97(5):1002–1020. doi: 10.1016/j.ijrobp.2016.11.056.
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Strigari L, Arcangeli S, et al. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials. Crit Rev Oncol Hematol. 2015;95(3):387–396. doi: 10.1016/j.critrevonc.2015.04.006.
   PubMed Web of Science ®Google Scholar
• Martini T, Mayr R, Wehrberger C, et al. Comparison of radical cystectomy with conservative treatment in geriatric (≥80) patients with muscle-invasive bladder cancer. Int Braz J Urol. 2013;39(5):622–630. doi: 10.1590/S1677-5538.IBJU.2013.05.03.
   PubMed Web of Science ®Google Scholar
• Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–137. doi: 10.1016/j.eururo.2014.02.038.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Hall E, Lewis R, et al. Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 phase III randomised controlled trial. Eur Urol. 2020;77(2):260–268. doi: 10.1016/j.eururo.2019.11.001.
   PubMed Web of Science ®Google Scholar
• James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–1488. doi: 10.1056/NEJMoa1106106.
   PubMed Web of Science ®Google Scholar
• Mathieu R, Lucca I, Klatte T, et al. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy? Curr Opin Urol. 2015;25(5):476–482. doi: 10.1097/MOU.0000000000000203.
   PubMed Web of Science ®Google Scholar
• Mottet N, Ribal MJ, Boyle H, et al. Management of bladder cancer in older patients: position paper of a SIOG task force. J Geriatr Oncol. 2020;11(7):1043–1053. doi: 10.1016/j.jgo.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Maebayashi T, Ishibashi N, Aizawa T, et al. Radiotherapy for muscle-invasive bladder cancer in very elderly patients. Anticancer Res. 2016;36(9):4763–4769. doi: 10.21873/anticanres.11033.
   PubMed Web of Science ®Google Scholar
• Datta NR, Stutz E, Puric E, et al. A pilot study of radiotherapy and local hyperthermia in elderly patients With Muscle-Invasive bladder cancers unfit for definitive surgery or chemoradiotherapy. Front Oncol. 2019;9:889. doi: 10.3389/fonc.2019.00889.
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487–497. doi: 10.1016/s1470-2045(02)00818-5.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol). 2007;19(6):418–426. doi: 10.1016/j.clon.2007.03.015.
   PubMed Web of Science ®Google Scholar
• Oei AL, Vriend LEM, Crezee J, et al. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015;10(1):165. doi: 10.1186/s13014-015-0462-0.
   PubMed Web of Science ®Google Scholar
• Oei AL, Kok HP, Oei SB, et al. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. Adv Drug Deliv Rev. 2020;163-164:84–97. doi: 10.1016/j.addr.2020.01.003.
   PubMed Web of Science ®Google Scholar
• Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International collaborative hyperthermia group. Int J Radiat Oncol Biol Phys. 1996;35(4):731–744. doi: 10.1016/0360-3016(96)00154-x.
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Wessalowski R, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2017;18(11):e630–570. doi: 10.1016/S1470-2045(10)70071-1.
   PubMed Web of Science ®Google Scholar
• Dobšíček Trefná H, Crezee J, Schmidt M, et al. Quality assurance guidelines for superficial hyperthermia clinical trials: II. Technical requirements for heating devices. Strahlenther Onkol. 2017;193(5):351–366. doi: 10.1007/s00066-017-1106-0.
   PubMed Web of Science ®Google Scholar
• Ademaj A, Veltsista DP, Ghadjar P, et al. Clinical evidence for thermometric parameters to guide hyperthermia treatment. Cancers (Basel). 2022;14(3):625. doi: 10.3390/cancers14030625.
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800. doi: 10.1016/0360-3016(84)90379-1.
   PubMed Web of Science ®Google Scholar
• Lagendijk JJ, Van Rhoon GC, Hornsleth SN, et al. ESHO quality assurance guidelines for regional hyperthermia. Int J Hyperthermia. 1998;14(2):125–133. doi: 10.3109/02656739809018219.
   PubMed Web of Science ®Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, et al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia. Strahlenther Onkol. 2012;188 Suppl 2(S2):198–211. doi: 10.1007/s00066-012-0176-2.
   PubMedGoogle Scholar
• Turgeon G-A, Souhami L, Cury FL, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):326–331. doi: 10.1016/j.ijrobp.2013.11.005.
   PubMed Web of Science ®Google Scholar
• Ademaj A, Puric E, Timm O, et al. Real world analysis of quality of life and toxicity in cancer patients treated with hyperthermia combined with radio(chemo)therapy. Cancers (Basel). 2023;15(4):1241. doi: 10.3390/cancers15041241.
   PubMed Web of Science ®Google Scholar
• Bakker A, van der Zee J, van Tienhoven G, et al. Temperature and thermal dose during radiotherapy and hyperthermia for recurrent breast cancer are related to clinical outcome and thermal toxicity: a systematic review. Int J Hyperthermia. 2019;36(1):1024–1039.
   PubMed Web of Science ®Google Scholar
• Hafeez S, McDonald F, Lalondrelle S, et al. Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys. 2017;98(1):115–122. doi: 10.1016/j.ijrobp.2017.01.239.
   PubMed Web of Science ®Google Scholar
• Tree AC, Jones K, Hafeez S, et al. Dose-limiting urinary toxicity With pembrolizumab combined With weekly hypofractionated radiation therapy in bladder cancer. Int J Radiat Oncol Biol Phys. 2018;101(5):1168–1171. doi: 10.1016/j.ijrobp.2018.04.070.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Porta N, Hall E, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021;22(2):246–255. doi: 10.1016/S1470-2045(20)30607-0.
   PubMed Web of Science ®Google Scholar
• Ohtsubo T, Saito H, Tanaka N, et al. Enhancement of cisplatin sensitivity and platinum uptake by 40 degrees C hyperthermia in resistant cells. Cancer Lett. 1997;119(1):47–52. doi: 10.1016/s0304-3835(97)00250-4.
   PubMed Web of Science ®Google Scholar
• Oleson JR, Sim DA, Manning MR, et al. Analysis of prognostic variables in hyperthermia treatment of 161 patients. Int J Radiat Oncol Biol Phys. 1984;10(12):2231–2239. doi: 10.1016/0360-3016(84)90228-1.
   PubMed Web of Science ®Google Scholar
• Leopold KA, Dewhirst M, Samulski T, et al. Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1992;22(5):989–998. doi: 10.1016/0360-3016(92)90798-m.
   PubMed Web of Science ®Google Scholar
• Kroesen M, Mulder HT, van Holthe JML, et al. The effect of the time interval Between radiation and hyperthermia on clinical outcome in 400 locally advanced cervical carcinoma patients. Front Oncol. 2019;9:134. doi: 10.3389/fonc.2019.00134.
   PubMed Web of Science ®Google Scholar
• Franckena M, Fatehi D, de Bruijne M, et al. Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia. Eur J Cancer. 2009;45(11):1969–1978. doi: 10.1016/j.ejca.2009.03.009.
   PubMed Web of Science ®Google Scholar
• Kapp DS, Cox RS. Thermal treatment parameters are most predictive of outcome in patients with single tumor nodules per treatment field in recurrent adenocarcinoma of the breast. Int J Radiat Oncol Biol Phys. 1995;33(4):887–899. doi: 10.1016/0360-3016(95)00212-4.
   PubMed Web of Science ®Google Scholar
• Thrall DE, LaRue SM, Yu D, et al. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res. 2005;11(14):5206–5214. doi: 10.1158/1078-0432.CCR-05-0091.
   PubMed Web of Science ®Google Scholar
• Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 2005;23(13):3079–3085. doi: 10.1200/JCO.2005.05.520.
   PubMed Web of Science ®Google Scholar
• Dinges S, Harder C, Wurm R, et al. Combined treatment of inoperable carcinomas of the uterine cervix with radiotherapy and regional hyperthermia. Results of a phase II trial. Strahlenther Onkol. 1998;174(10):517–521. doi: 10.1007/BF03038984.
   PubMed Web of Science ®Google Scholar
• Gani C, Lamprecht U, Ziegler A, et al. Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. Radiother Oncol. 2021;159:155–160. doi: 10.1016/j.radonc.2021.03.011.
   PubMed Web of Science ®Google Scholar
• Harima Y, Ohguri T, Imada H, et al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer. Int J Hyperthermia. 2016;32(7):801–808. doi: 10.1080/02656736.2016.1213430.
   PubMed Web of Science ®Google Scholar
• Wust P, Seebass M, et al., et al. Electromagnetic deep heating technology. In Thermoradiotherapy and thermochemotherapy: biology, physiology, physics., Seegenschmiedt, M.HEds.; Springer Berlin Heidelberg: berlin, Heidelberg, 1995; pp. 219–251.
   Google Scholar
• Paulsen KD, Geimer S, Tang J, et al. Optimization of pelvic heating rate distributions with electromagnetic phased arrays. Int J Hyperthermia. 1999;15(3):157–186. doi: 10.1080/026567399285701.
   PubMed Web of Science ®Google Scholar
• Fatehi D, van der Zee J, de Bruijne M, et al. RF-power and temperature data analysis of 444 patients with primary cervical cancer: deep hyperthermia using the sigma-60 applicator is reproducible. Int J Hyperthermia. 2007;23(8):623–643. doi: 10.1080/02656730701827557.
   PubMed Web of Science ®Google Scholar
• Merten R, Ott O, Haderlein M, et al. Long-Term experience of chemoradiotherapy combined with deep regional hyperthermia for organ preservation in High-Risk bladder cancer (ta, tis, T1, T2). Oncologist. 2019;24(12):e1341–e50. doi: 10.1634/theoncologist.2018-0280.
   PubMed Web of Science ®Google Scholar